Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | CYP2E1 | P05181 | 6/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.71 |
| ▸ | NOS3 | P29474 | 1/20 | 0.64 |
| ▸ | NOS1 | P29475 | 1/20 | 0.64 |
| ▸ | NOS2 | P35228 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 8/20 | 0.64 |
| ▸ | NPC1 | O15118 | 7/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11687988 | 0.98 | CYP1A2 (0.97) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| Water SCHEMBL4488115 | 0.98 | CYP1A2 (0.97) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL25319196 | 0.86 | CYP1A2 (0.75) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL28724342 | 0.86 | CYP1A2 (0.75) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL14304931 | 0.86 | CYP1A2 (0.75) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL6483161 | 0.84 | CYP1A2 (0.72) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL10920495 | 0.84 | CYP1A2 (0.70) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL11684920 | 0.84 | CYP2E1 (0.73) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL7850535 | 0.84 | CYP1A2 (0.71) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 | |
| SCHEMBL10574131 | 0.84 | CYP1A2 (0.72) | CYP1A2CYP2E1CYP2C8CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1466897-B1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | DIPHARMA FRANCIS SRL (IT) | 2008-12-17 | — | — | EP | claimed |
| EP-1421076-B1 | HYDRATES OF OPTIONALLY SUBSTITUTED 2-(2-PYRIDINYL)METHYLTHIO-1H-BENZIMIDAZOLES AND METHOD FOR THE PRODUCTION THEREOF | GRUENENTHAL GMBH (DE) | 2007-10-10 | — | — | EP | claimed |
| US-6998490-B2 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. (IT) | 2006-02-14 | — | — | US | claimed |
| EP-1466897-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | Dipharma S.p.A. (IT) | 2004-10-13 | — | — | EP | claimed |
| US-20040192929-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. ABBREVIATED DIPHARMA S.P.A. | 2004-09-30 | — | — | US | claimed |
| EP-1270555-B1 | METHOD FOR OXIDIZING A THIOETHER GROUP INTO A SULFOXIDE GROUP | ESTEVE QUIMICA SA (ES) | 2004-08-25 | — | — | EP | claimed |
| US-20040158072-A1 | Hydrates of optionally substituted 2-(2-pyridinyl) methylthio-1H-benzimidazoles and process for the production thereof | GRUNENTHAL GMBH (DE) | 2004-08-12 | — | — | US | claimed |
| US-6603009-B2 | Oxidation of a thioether to a sulfoxide using sodium percarbonate and a molybdenum salt as catalyst; making lansoprazole, omeprazole, rabeprazole, and pantoprazole | ESTEVE QUIMICA, S.A. (ES) | 2003-08-05 | — | — | US | claimed |
| US-20030028030-A1 | Method for oxidizing a thioether group into a sulfoxide group | ESTEVE QUIMICA, S.A. (ES) | 2003-02-06 | — | — | US | claimed |
| EP-1270555-A1 | METHOD FOR OXIDIZING A THIOETHER GROUP INTO A SULFOXIDE GROUP | ESTEVE QUIMICA, S.A. (ES) | 2003-01-02 | — | — | EP | claimed |
| CN-1070192-C | Thipyridines for use in control of helicobacter bacteria | BYK GULDEN LOMBERG CHEM FAB (DE) | 2001-08-29 | — | — | CN | claimed |
| EP-0645140-B1 | Compositions for rectal administration containing benzimidazoles and fatty acid salts | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-12-02 | — | — | EP | claimed |
| CN-1155284-A | Thipyridines for use in control of helicobacter bacteria | BYK GULDEN LOMBERG CHEM FAB (DE) | 1997-07-23 | — | — | CN | claimed |
| EP-0649305-A1 | BENZIMIDAZOLES FOR ALLEVIATING STOMACH ULCERS IN SWINE | MONSANTO COMPANY (US) | 1995-04-26 | — | — | EP | claimed |
| US-5389664-A | Administering benzimidazole compounds to inhibit at pase activity | MONSANTO COMPANY (US) | 1995-02-14 | — | — | US | claimed |
| WO-1994001107-A1 | BENZIMIDAZOLES FOR ALLEVIATING STOMACH ULCERS IN SWINE | MONSANTO COMPANY (US) | 1994-01-20 | — | — | WO | claimed |
| EP-0166287-B1 | DIALKOXYRIDINES, PROCESS FOR THEIR PREPARATION, THEIR APPLICATION AND MEDICAMENTS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1989-08-23 | — | — | EP | claimed |
| JP-1131176-A | — | — | None | — | — | JP | disclosed |
| US-4472409-A | ANTIULCER AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-09-18 | — | — | US | disclosed |
| US-4045563-A | Substituted 2-[pyridylalkylenesulfinyl]-benzimidazoles with gastric acid secretion inhibiting effects | AB HASSLE (SW) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158072-A1 | Hydrates of optionally substituted 2-(2-pyridinyl) methylthio-1H-benzimidazoles and process for the production thereof | BHMT2, H1-4, TBCB | CYP1A2 245/4885CYP2E1 181/4885CYP2C8 342/4885 |
| US-20030028030-A1 | Method for oxidizing a thioether group into a sulfoxide group | CBR1, CBR3, SCO2 | CYP1A2 2157/4885CYP2E1 154/4885CYP2C8 1044/4885 |
| US-20040192929-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | STS, MPST, SULT2A1 | CYP1A2 402/4885CYP2E1 99/4885CYP2C8 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.